NCT05919342 Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"
| NCT ID | NCT05919342 |
| Status | Recruiting |
| Phase | — |
| Sponsor | NHS Greater Glasgow and Clyde |
| Condition | Heart Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,904 participants |
| Start Date | 2022-12-22 |
| Primary Completion | 2024-06-21 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 3,904 participants in total. It began in 2022-12-22 with a primary completion date of 2024-06-21.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an international prospective, multicentre, unblinded, randomised-controlled trial. The primary aim is to assess a targeted screening strategy to detect undiagnosed heart failure in high-risk patients.
Eligibility Criteria
Inclusion Criteria: * Male or female ≥40 years of age * Informed consent * Two or more of the following risk factors for heart failure: 1. Coronary artery disease (either a previous documented type 1 myocardial infarction or coronary artery bypass grafting or percutaneous coronary intervention or documented stenosis of an epicardial coronary artery \[50% left main stem or \>70% left anterior descending, circumflex or right coronary artery\]) 2. An established diagnosis of diabetes (type 1 or type 2) 3. Persistent or permanent atrial fibrillation (not paroxysmal atrial fibrillation) 4. Previous ischemic or embolic stroke 5. Peripheral arterial disease (previous surgical or percutaneous revascularisation or a documented stenosis greater than 50% of a major peripheral arterial vessel). 6. Chronic kidney disease (defined as an estimated glomerular filtration rate \<60mL/min/1.73m2 or eGFR 60-90mL/min/1.73m2 and UACR \>300mg/g). 7. Regular loop diuretic use (any dose at any dosing interval) for \>30 days. 8. COPD (evidenced by one of the following: PFTs showing airway obstruction, diagnosis by respiratory physician, CT scan reporting presence of emphysema or treatment with national guideline advocated COPD therapy). Exclusion Criteria: * Inability to give informed consent e.g., due to significant cognitive impairment * Previous documented diagnosis of heart failure * Current renal replacement therapy * Anyone who, in the investigators' opinion, is not suitable to participate in the trial for other reasons e.g., a diagnosis which may compromise survival over the study period
Contact & Investigator
Mark C Petrie, MbChB
PRINCIPAL INVESTIGATOR
University of Glasgow
Frequently Asked Questions
Who can join the NCT05919342 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05919342 currently recruiting?
Yes, NCT05919342 is actively recruiting participants. Contact the research team at mark.petrie@glasgow.ac.uk for enrollment information.
Where is the NCT05919342 trial being conducted?
This trial is being conducted at Cleveland, United States, Vancouver, Canada, Montreal, Canada, Copenhagen, Denmark and 3 additional locations.
Who is sponsoring the NCT05919342 clinical trial?
NCT05919342 is sponsored by NHS Greater Glasgow and Clyde. The principal investigator is Mark C Petrie, MbChB at University of Glasgow. The trial plans to enroll 3,904 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.